TP53 and neoplasm: Intriguingly, research on AsiDNA has revealed a potentially superior therapeutic strategy—this novel agent uniquely induces G1/S cell cycle arrest in normal epithelial cells and fibroblasts through activation of the DNA-PK/p53/p21 pathway, a protective mechanism absent in p53-deficient tumor cells [157,175,176].